Introduction of medical products into healthcare practice and costs reimbursement: European experience
https://doi.org/10.17749/2070-4909.2018.11.2.059-066
Abstract
in the present article, we review the ways of introducing medical products into healthcare practice in countries of the european Union and compare them with the Russian experience. in this analysis, we underscore the existing differences but also identify the common aspects, for example, the mandatory stage of integrated assessment; all those are described in detail in the review. The eU experience should be considered when introducing medical products into the healthcare practice in the Russian Federation. The comprehensive assessment of new technologies will provide for the transparency of the proposed system.
About the Authors
V. V. Omelyanovsky
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education ; Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution.
Russian Federation
Omelyanovsky Vitaliy Vladimirovich – MD, PhD, Professor, Director of the Center for Technology Assessment in Healthcare, Research Financial Institute. 82 Vernadskogo prospect, Moscow 119571; 3-2 Nastasyinsky pereulok, Moscow 127006.
Russian Federation
Omelyanovsky Vitaliy Vladimirovich – MD, PhD, Professor, Director of the Center for Technology Assessment in Healthcare, Research Financial Institute. 82 Vernadskogo prospect, Moscow 119571; 3-2 Nastasyinsky pereulok, Moscow 127006.
S. S. Otstavnov
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation ; Moscow Institute of Physics and Technology (State University).
Russian Federation
Otstavnov Stanislav Sergeevich – PhD, Chief Specialist, Department of the Development and External Affairs, Lecturer, Chair of Technological Tntrepreneurship. 10-5 Khokhlovskii pereulok, Moscow 109028; 9 Institutskiy per., Dolgoprudny 141701, Moscow Region.
Russian Federation
Otstavnov Stanislav Sergeevich – PhD, Chief Specialist, Department of the Development and External Affairs, Lecturer, Chair of Technological Tntrepreneurship. 10-5 Khokhlovskii pereulok, Moscow 109028; 9 Institutskiy per., Dolgoprudny 141701, Moscow Region.
N. Z. Musina
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution ; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia.
Russian Federation
Musina Nuriya Zagitovna – PhD, Lecturer, Department of Pharmacology, Faculty of Pharmacy, Senior Researcher. 3-2 Nastasyinsky pereulok, Moscow 127006; 8-2 Trubetskaya, Str., Moscow 119048.
Russian Federation
Musina Nuriya Zagitovna – PhD, Lecturer, Department of Pharmacology, Faculty of Pharmacy, Senior Researcher. 3-2 Nastasyinsky pereulok, Moscow 127006; 8-2 Trubetskaya, Str., Moscow 119048.
V. S. Dombrovskii
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education; Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dombrovskii Vladislav Sergeevich – Chief Specialist, Department of Methodological Support of Integrated Healthcare Technology, Researcher at the Center for Healthcare Technology Assessment.
82 Vernadskogo prospect, Moscow 119571; 10-5 Khokhlovskii pereulok, Moscow 109028.
References
1. Otstavnov S. S., Otstavnov N. S. MGTU im. n. e. Baumana. elektron. zhurn. 2014; 1 (in Russian). [electronic resource] URL: http://sntbul.bmstu.ru/doc/681067.html. Accessed: 20.05.2018.
2. Otstavnov S. S., Krylov Yu. V., Zlenko D., Alekseenko D. Remedium (in Russian). 2014; 1-2: 47-53.
3. Jones C. Market Access Roadmap for Medical Devices in Europe. 2017.
4. Lemeshko V. A., Musina N. Z., Fedyaeva V. K. FARMAkOekOnOMikA. Sovremennaya farmakoekonomika i farmakoepidemio- logiya / FARMAkOekOnOMikA. Modern pharmacoeconomics and pharmacoepidemiology (in Russian). 2017; 10 (4): 25-30. DOI: 10.17749/2070-4909.2017.10.4.025-030.
5. Omelyanovskij V. V. FARMAkOekOnOMikA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAkOekOnOMikA. Modern pharmacoeconomics and pharmacoepidemiology (in Russian). 2014; 7 (4): 36-41.
6. Fedyaev D. V., Maksimova L. V., Omelyanovskij V. V. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2014; 1 (15): 57-64.
7. Tatarinov A. P., Lukyanceva D. V., Mel’nikova L. S., Omelyanovskij V. V. FARMAkOekOnOMikA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAkOekOnOMikA. Modern pharmacoeconomics and pharmacoepidemiology (in Russian). 2016; 9 (3): 6067. DOI:10.17749/2070-4909.2016.9.3.060-067.
8. Otstavnov S. S., Breusov A. V., Otstavnov N. S., Breusov R. A. Vestnik Rossijskogo universiteta druzhby narodov. Seriya: Medicina (in Russian). 2016; 4: 158-167.
9. Kitcmann H., Fal’ko S. G. innovacii v menedzhmente (in Russian). 2017; 1 (11): 26-31.
10. Otstavnov S. S., Otstavnov N. S., Breusov A. V. innovacii v menedzhmente (in Russian). 2017; 14: 56-63.
11. Commission nationale d’evaluation des dispositifs médicaux et des technologies de santé (CNEDiMTS). Reglement interieur. Adopté le 12 janvier 2016. Modifié le 09 janvier 2018. [electronic resource] URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/reglement_cepp.pdf. Accessed: 20.05.2018.
12. Medical device assessment in France. Guidebook. Haute Autorité de Santé – 2009. [electronic resource] URL: https://www.hassante.fr/portail/upload/docs/application/pdf/2010-03/guide_dm_gb_050310_2010-03-12_12-45-33_878.pdf. Accessed: 20.05.2018.
13. Managing Medical Devices Guidance for healthcare and social services organisations. Medicines and Healthcare Products Regulatory Agency. April 2015. [electronic resource] URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/421028/Managing_medical_devices_-_ Apr_2015.pdf. Accessed: 20.05.2018.
14. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). ISPOR Global Health Care Systems Road Map: UK – Medical Device Pricing and Coverage. [electronic resource] URL: https://www.ispor.org/HTARoadMaps/UKDiagnostics.asp. Accessed: 20.05.2018.
15. European Med Tech and IVD Reimbursement Consulting Ltd. Reimbursement summary for angioplasty of arteries of lower extremities with stenting using bare metal and drug-eluting stents. [electronic resource] URL: https://mtrconsult.com/news/reimbursement-summaryangioplasty-arteries-lower-extremities-stenting-using-bare-metal-and. Accessed: 20.05.2018.
16. NHS England. New system for buying and supplying high-cost medical devices in specialised services. [electronic resource] URL: https://www.england.nhs.uk/commissioning/spec-services/key-docs/medical-devices/. Accessed: 20.05.2018.
17. Reimbursement of Medical Devices in Germany 2017. AiM. An IGES Group company. [electronic resource] URL: http://www.iges.com/e6666/e15771/e20489/e20491/e20493/AiM_Reimbursement_of_Medical_Devices_in_Germany_ger.pdf . Accessed: 20.05.2018.
18. Reimbursement of medical devices in Germany Market access in the light of the health and certification system. [electronic resource] URL: https://www.exportinitiative-gesundheitswirtschaft.de/EIG/Redaktion/EN/Publikationen/2015-06-12-hmg-publication-reimbursement-medicaldevices-englisch.pdf?__blob=publicationFile&v=5. Accessed: 20.05.2018.
19. France G., Taroni F., Donatini A. The Italian health-care system. Health econ. 2005 Sep; 14 (S1): 187-202.
20. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). ISPOR Global Health Care Systems Road Map: Italy – Medical Device Pricing and Coverage. February 2012. [electronic resource] URL: https://www.ispor.org/HTARoadMaps/Italy/Italy_MDD.asp. Accessed: 20.05.2018.
21. Andreeva N. S., Rebrova O. Yu., Zorin N. A., Avksent’eva M. V., Omel’yanovskij V. V. Medicinskie tekhnologii. Ocenka i vybor. 2012; 4 (10): 10-24.
Review
For citations:
Omelyanovsky V.V., Otstavnov S.S., Musina N.Z., Dombrovskii V.S. Introduction of medical products into healthcare practice and costs reimbursement: European experience. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(2):59-66. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.2.059-066
Views: 891
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 